
    
      Patients with functional dyspepsia were randomly assigned (1:1) to receive either
      UI05MSP015CT (15 mg once daily before breakfast, study group) or mosapride (5 mg three times
      a day before each meal, control group) and corresponding placebo t.i.d. or q.d. for 4 weeks.
    
  